-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QyZRftULfGYuWZzUlxbKRH48Z9m/UH99SVslvlDSoikDDk8/9pLlHoCs7nFhlFQh feXb9W0lRMKndrX/o0KKIg== 0001137050-08-000114.txt : 20080409 0001137050-08-000114.hdr.sgml : 20080409 20080409131431 ACCESSION NUMBER: 0001137050-08-000114 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080407 ITEM INFORMATION: Other Events FILED AS OF DATE: 20080409 DATE AS OF CHANGE: 20080409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: China Bio-Immunity CORP CENTRAL INDEX KEY: 0001345479 STANDARD INDUSTRIAL CLASSIFICATION: [3949] IRS NUMBER: 202815911 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51760 FILM NUMBER: 08747200 BUSINESS ADDRESS: STREET 1: 10-44 CHESTER LE BLVD. CITY: TORONTO STATE: A6 ZIP: M1W2M8 BUSINESS PHONE: 647-268-3809 MAIL ADDRESS: STREET 1: 10-44 CHESTER LE BLVD. CITY: TORONTO STATE: A6 ZIP: M1W2M8 FORMER COMPANY: FORMER CONFORMED NAME: Easy Golf CORP DATE OF NAME CHANGE: 20051128 8-K 1 chhb8kitem801reversestockspl.htm UNITED STATES

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Event: April 7, 2008


CHINA BIO-IMMUNITY CORPORATION

(Exact name of registrant as specified in its charter)


Nevada

000-51760

20-2815911

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

10-44 Chester Le Blvd,

Toronto, ON M1W2M8

CANADA

(Address of principal executive offices)


Registrant’s telephone number, including area code: 1-647-268-3809



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






ITEM 8.01 - OTHER EVENTS  


Effective April 7, 2008, China Bio-Immunity Corporation (the “Registrant”) completed a one-for-two (1-for-2) reverse stock split of its outstanding shares of common stock (the “Reverse Split”).   As a result of the Reverse Split the Registrant’s common stock ceased trading under the symbol “CHBB” and began trading under the symbol “CHHB”.


Through the Reverse Spilt, the total number of outstanding shares of the Registrant’s common stock was reduced from 3,506,428 to approximately 1,753,214 shares presently issued and outstanding. The Reverse Split affected all of the holders of all classes of the Registrant’s common stock uniformly and did not affect any stockholder’s percentage ownership interest in the Registrant or proportionate voting power, except for insignificant changes that will result from the rounding of fractional shares.  The Reverse Split did not cause a reduction in the Registrant’s 50,000,000 shares of authorized common stock.


No fractional shares were issued for any fractional share interest created by the Reverse Split; shareholders received a full share of common stock for any fractional share interests created by the Reverse Split.


SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


CHINA BIO-IMMUNITY CORPORATION


Date: April 8, 2008


/s/ Quanfeng Wang

---------------------------------
By:  Quanfeng Wang
Its:   Chief Executive Officer
       







-----END PRIVACY-ENHANCED MESSAGE-----